General Information
Akcea-Ionis Fatty Liver CS02
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects with Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and Nonalcoholic Fatty Liver Disease (NAFLD)
| Protocol | ISIS 703802-CS02 |
|---|---|
| Identifier | Billcode 8369290 |
| UID | 07301d19-ca82-482b-8487-7855679efd03 |
| Status | Done - Archived |
| Phase | 2 |
| Category | Fatty Liver / Adult |
| Launch Year | 2018 |
| NCT Number | - |
| Created | 2017-10-11 16:44 |
| Last Updated | 2017-10-11 16:44 |
Description
No description provided.
Comment
CRI
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2019-04-15 | No |
| Enrollment Open | 2018-04-16 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2018-02-15 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2020-04-21 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | Miss, Salomon | SMiss | No |
| Coordinator | Diaz-Chavez, Mayra | MDiaz-Chavez | No |
| Regulatory | Ramirez, Claudia | CRamirez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Akcea Ionis Pharmaceuticals |
|---|---|
| Division | Akcea Ionis Pharmaceuticals |
| Team | Akcea Ionis Pharmaceuticals |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | Covance -LabCorp Drug Development |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
